NASDAQ:RDUS

Radius Health Stock Forecast, Price & News

$18.68
-0.13 (-0.69 %)
(As of 06/14/2021 10:38 AM ET)
Add
Compare
Today's Range
$18.68
$19.19
50-Day Range
$18.09
$22.42
52-Week Range
$10.15
$26.16
Volume349 shs
Average Volume414,623 shs
Market Capitalization$882.50 million
P/E RatioN/A
Dividend YieldN/A
Beta0.97
30 days | 90 days | 365 days | Advanced Chart
Receive RDUS News and Ratings via Email

Sign-up to receive the latest news and ratings for Radius Health and its competitors with MarketBeat's FREE daily newsletter.


Radius Health logo

About Radius Health

Radius Health, Inc., a biopharmaceutical company, develops and commercializes endocrine and other therapeutics. The company's commercial product is TYMLOS, an abaloparatide injection for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide-SC, which is in Phase III clinical trials for the treatment of osteoporosis in men; abaloparatide-TD, a short-wear-time transdermal patch that is in Phase III clinical trials to treat postmenopausal women with osteoporosis; Elacestrant (RAD1901), a selective estrogen receptor degrader, which is in Phase III clinical trials for the treatment of hormone receptor-positive breast cancer; and RAD011, which is in Phase II clinical trials for treatment of hyperphagia related to Prader-Willi syndrome. The company has collaborations and license agreements with 3M Company; Ipsen Pharma SAS; Teijin Limited; Berlin-Chemie AG; Eisai Co. Ltd.; and Duke University. Radius Health, Inc. was founded in 2003 and is headquartered in Boston, Massachusetts.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.30 out of 5 stars

Medical Sector

860th out of 2,099 stocks

Pharmaceutical Preparations Industry

417th out of 831 stocks

Analyst Opinion: 3.2Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Radius Health (NASDAQ:RDUS) Frequently Asked Questions

Is Radius Health a buy right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Radius Health in the last twelve months. There are currently 5 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Radius Health stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in RDUS, but not buy additional shares or sell existing shares.
View analyst ratings for Radius Health
or view top-rated stocks.

What stocks does MarketBeat like better than Radius Health?

Wall Street analysts have given Radius Health a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Radius Health wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Radius Health's next earnings date?

Radius Health is scheduled to release its next quarterly earnings announcement on Monday, August 9th 2021.
View our earnings forecast for Radius Health
.

How were Radius Health's earnings last quarter?

Radius Health, Inc. (NASDAQ:RDUS) released its earnings results on Friday, May, 7th. The biopharmaceutical company reported ($0.34) EPS for the quarter, topping the consensus estimate of ($0.42) by $0.08. The biopharmaceutical company earned $56.26 million during the quarter, compared to analysts' expectations of $59.28 million.
View Radius Health's earnings history
.

How has Radius Health's stock been impacted by COVID-19 (Coronavirus)?

Radius Health's stock was trading at $16.06 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, RDUS stock has increased by 19.5% and is now trading at $19.19.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for RDUS?

8 equities research analysts have issued 12 month price targets for Radius Health's stock. Their forecasts range from $14.00 to $33.00. On average, they expect Radius Health's share price to reach $25.13 in the next twelve months. This suggests a possible upside of 30.9% from the stock's current price.
View analysts' price targets for Radius Health
or view top-rated stocks among Wall Street analysts.

Who are Radius Health's key executives?

Radius Health's management team includes the following people:
  • Mr. G. Kelly Martin, CEO, Pres & Director (Age 62, Pay $612.37k)
  • Mr. James G. Chopas, CFO, VP, Treasurer, Principal Fin. Officer & Principal Accounting Officer (Age 54, Pay $355.52k)
  • Mr. Salvador Grausso, Sr. VP & Chief Commercial Officer (Age 46, Pay $530.42k)
  • Dr. Stavros C. Manolagas, Founder & Member of the Scientific Advisory Board
  • Dr. John Thomas Potts Jr., Founder & Member of the Scientific Advisory Board (Age 89)
  • Dr. Michael Rosenblatt, Founder, Board Observer & Member of Scientific Advisory Board (Age 73)
  • Dr. John A. Katzenellenbogen, Founder & Member of the Scientific Advisory Board
  • Ms. Elhan Webb C.F.A., Head of Investor Relations & External Communications
  • Ms. Averi Price, Gen. Counsel, Chief Compliance Officer & Sec.
  • Ms. Chhaya Shah, Sr. VP & Chief Bus. Officer (Age 57)

Who are some of Radius Health's key competitors?

What other stocks do shareholders of Radius Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Radius Health investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Amarin (AMRN), ACADIA Pharmaceuticals (ACAD), Exact Sciences (EXAS), Cara Therapeutics (CARA), OPKO Health (OPK), Portola Pharmaceuticals (PTLA), Micron Technology (MU) and Netflix (NFLX).

What is Radius Health's stock symbol?

Radius Health trades on the NASDAQ under the ticker symbol "RDUS."

Who are Radius Health's major shareholders?

Radius Health's stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (8.26%), Artisan Partners Limited Partnership (3.41%), Camber Capital Management LP (3.18%), Geode Capital Management LLC (1.70%), Northern Trust Corp (1.12%) and Rubric Capital Management LP (0.95%). Company insiders that own Radius Health stock include Anthony Rosenberg, Growth N V Biotech, James George Chopas and Target N V Biotech.
View institutional ownership trends for Radius Health
.

Which major investors are selling Radius Health stock?

RDUS stock was sold by a variety of institutional investors in the last quarter, including D. E. Shaw & Co. Inc., BlackRock Inc., Camber Capital Management LP, Renaissance Technologies LLC, Clearline Capital LP, Rubric Capital Management LP, Russell Investments Group Ltd., and Credit Suisse AG.
View insider buying and selling activity for Radius Health
or view top insider-selling stocks.

Which major investors are buying Radius Health stock?

RDUS stock was bought by a variety of institutional investors in the last quarter, including Artisan Partners Limited Partnership, Arrowstreet Capital Limited Partnership, Hennion & Walsh Asset Management Inc., Federated Hermes Inc., Globeflex Capital L P, Voloridge Investment Management LLC, Citigroup Inc., and Millennium Management LLC. Company insiders that have bought Radius Health stock in the last two years include Growth N V Biotech, and Target N V Biotech.
View insider buying and selling activity for Radius Health
or or view top insider-buying stocks.

How do I buy shares of Radius Health?

Shares of RDUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Radius Health's stock price today?

One share of RDUS stock can currently be purchased for approximately $19.19.

How much money does Radius Health make?

Radius Health has a market capitalization of $906.59 million and generates $238.65 million in revenue each year. The biopharmaceutical company earns $-109,210,000.00 in net income (profit) each year or ($2.35) on an earnings per share basis.

How many employees does Radius Health have?

Radius Health employs 310 workers across the globe.

What is Radius Health's official website?

The official website for Radius Health is www.radiuspharm.com.

Where are Radius Health's headquarters?

Radius Health is headquartered at 950 WINTER STREET, WALTHAM MA, 02451.

How can I contact Radius Health?

Radius Health's mailing address is 950 WINTER STREET, WALTHAM MA, 02451. The biopharmaceutical company can be reached via phone at 617-551-4000 or via email at [email protected]


This page was last updated on 6/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.